Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

The companies said Thursday that they voluntarily withdrew the accelerated approval request for patritumab deruxtecan in ...

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...

Oric Pharmaceuticals raises $125M for Phase 3 prostate cancer drug ORIC-944 after positive early results, with study planned ...

Sanofi partners in Vietnam, Almac hits £1B sales, Quadria raises $1.07B, CurifyLabs gets funding, BrainStorm signs with ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

EDO51 for Duchenne muscular dystrophy after Phase 2 trial failure, abandons three preclinical programs, and pivots to focus ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...